FOLFOX

FOLFOX is a combination chemotherapy regimen built from three drugs: folinic acid (leucovorin), 5-fluorouracil (5-FU), and oxaliplatin. It is most commonly used for colorectal cancer but is also used in some peritoneal and gastrointestinal cancers, and occasionally as a treatment option for peritoneal mesothelioma when standard regimens have failed or are not tolerated.

Origin

The name is an acronym assembled from the regimen's components, FOLinic acid, Fluorouracil, and OXaliplatin. The regimen was developed and refined by French oncologists in the 1990s, notably by Aimery de Gramont and colleagues, and became a standard of care for advanced colorectal cancer after publication of pivotal trials around 2000.

Significance in Asbestos Context

FOLFOX is not a first-line treatment for pleural mesothelioma, but it can become directly relevant to asbestos patients in two ways. First, some patients with peritoneal mesothelioma (the abdominal form caused by asbestos) are treated with FOLFOX or oxaliplatin-based regimens, particularly when pemetrexed-platinum combinations stop working. Second, asbestos exposure has been associated in some studies with increased risk of gastrointestinal cancers including colorectal cancer, so a patient with both an asbestos history and a colon cancer diagnosis may receive FOLFOX as part of their treatment, and the costs, side effects, and impact on quality of life from that treatment can be part of a damages claim if causation is established.

Example Sentence

After her peritoneal mesothelioma progressed on pemetrexed and cisplatin, her oncologist started her on FOLFOX as a second-line regimen.

Related Terms

Peritoneal Mesothelioma, Pemetrexed, Cisplatin, Chemotherapy, Oxaliplatin, Second-Line Therapy

Notes

• Ask your oncologist specifically why FOLFOX is being recommended in your case (whether for peritoneal mesothelioma, a coexisting GI cancer, or as part of a clinical trial) and request that the rationale be documented in your medical record.
• Oxaliplatin commonly causes peripheral neuropathy (numbness, tingling, cold sensitivity in hands and feet) that can become permanent; report symptoms early so dosing can be adjusted, and keep a symptom diary, as neuropathy can be a significant component of non-economic damages.
• Keep complete records of infusion dates, drugs administered, dose modifications, hospitalizations for side effects, and out-of-pocket costs (port placement, anti-nausea drugs, neuropathy medications). These support both medical expense claims and pain-and-suffering damages.
• If you have peritoneal mesothelioma, ask whether you are a candidate for cytoreductive surgery with HIPEC before or after systemic chemotherapy, as treatment sequencing significantly affects outcomes.